{"prompt": "['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'Is life-threatening, or,', 'Note: The term \"life-threatening\" in the definition of \"serious\" refers to an event in which', 'the patient was at risk of death at the time of the event; it does not refer to an event which', 'hypothetically might have caused death if it were more severe.', 'Requires inpatient hospitalization or prolongation of existing hospitalization, or,', 'Results in persistent or significant disability/incapacity, or,', 'Is a congenital anomaly/birth defect.', 'Is a medically important event.', 'Medical and scientific judgment must be exercised in deciding whether expedited', 'reporting is appropriate in other situations, such as important medical events that may not', 'be immediately life-threatening or result in death or hospitalization but may jeopardize the', 'patient or may require medical or surgical intervention (ie, specific measures or corrective', 'treatment) to prevent one of the other outcomes listed in the definition above.', 'Note: The following list of medically important events is intended to serve as a guideline for', 'determining which condition has to be considered a medically important event. The list is not', 'intended to be exhaustive:', 'Intensive treatment in an emergency room or at home for:', '-', 'Allergic bronchospasm,', '-', 'Blood dyscrasias (ie, agranulocytosis, aplastic anemia, bone marrow aplasia,', 'myelodysplasia, pancytopenia, etc),', '-', 'Convulsions (seizures, epilepsy, epileptic fit, absence, etc).', 'Development of drug dependence or drug abuse.', 'ALT >3 X ULN + total bilirubin >2 X ULN or asymptomatic ALT increase >10 X ULN.', 'Suicide attempt or any event suggestive of suicidality.', 'Syncope, loss of consciousness (except if documented as a consequence of blood', 'sampling).', 'Bullous cutaneous eruptions.', 'Cancers diagnosed during the study or aggravated during the study (only if judged', 'unusual/significant by the Investigators in oncology studies).', 'Chronic neurodegenerative diseases (newly diagnosed) or aggravated during the study', '(only if judged unusual/significant by the Investigators in studies assessing specifically the', 'effect of a study drug on these diseases).', 'Suspected transmission of an infectious agent: if any suspected transmission of an', 'infectious agent via a medicinal product (eg, product contamination).', 'Hospitalization for the scheduled alemtuzumab infusions, not related with any AE, due to', 'Investigator decision or local requirement, will not be considered as an SAE.', '10.4.1.3 Adverse event of special interest', 'Any AESI will be reported to the Sponsor in the same timeframe as SAEs, ie, within 24 hours, as', 'detailed in Section 10.4.4.', 'Property of the Sanofi Group - strictly confidential', 'Page 78', 'VV-CLIN-02544065.0']['Amended Clinical Trial Protocol No. 05', '15-Dec-2021', 'GZ402673-EFC13429 - alemtuzumab', 'Version number: 1', 'An AESI is an AE (serious or nonserious) of scientific and medical concern specific to the', \"Sponsor's product or program, for which ongoing monitoring and immediate notification by the\", 'Investigator to the Sponsor is required. Such events may require further investigation in order to', 'characterize and understand them. Adverse events of special interest may be added, modified or', 'removed during a study by protocol amendment.', 'The following AE will be considered as an AESI:', 'Hypersensitivity or anaphylaxis.', 'Pregnancy occurring in a female patient entered in the clinical trial. It will be qualified as', 'an SAE only if it fulfills one of the seriousness criteria (see Section 10.4.1.2). Follow-up', 'of the pregnancy in a female participant is mandatory until the outcome has been', 'determined.', 'Symptomatic overdose (serious or nonserious) with IMP/non-investigational medicinal', 'product (NIMP).', '-', 'An overdose (accidental or intentional) with the IMP is an event suspected by the', 'Investigator or a nurse and defined as an increase of at least 30% of the dose to be', 'administered in the specified duration or if the dose is administered in less than half', 'the recommended duration of administration,', '-', 'An overdose with the NIMP is an event suspected by the Investigator or spontaneously', 'notified by the patient (not based on systematic pills count) and defined as at least', 'twice the intended dose within the intended therapeutic interval, adjusted according to', 'the tested drug,', '-', 'Of note, asymptomatic overdose has to be reported as a standard AE.', 'Increase in ALT (see the \"Increase in ALT\" flow diagram in Appendix B of the protocol).', 'Other product specific AESI(s):', '-', 'Autoimmune mediated conditions including but not limited to autoimmune', 'encephalitis, cytopenias, ITP, autoimmune hepatitis, nephropathies including anti-', 'glomerular basement membrane (GBM) disease, thyroid disorders and acquired', 'Hemophilia A (see Appendix B)', '-', 'Temporally associated* pulmonary alveolar hemorrhage', '-', 'Temporally associated* myocardial ischemia, myocardial infarction', '-', 'Temporally associated* stroke', '-', 'Temporally associated* cervicocephalic arterial dissection', '(* Temporally associated: 1 to 3 days after the last infusion)', '-', 'HLH,', '-', 'Progressive multifocal leukoencephalopathy (PML)', '-', 'Pneumonitis,', '-', 'Serious infections including serious opportunistic infections (eg, Listeria', 'infections, CMV, EBV), HPV associated with cervical dysplasia', '- Malignancy', '-', 'Thrombotic thrombocytopenic purpura', 'Property of the Sanofi Group - strictly confidential', 'Page 79', 'VV-CLIN-02544065 5.0']\n\n###\n\n", "completion": "END"}